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The place of ARBs in heart failure therapy: is
aldosterone suppression the key?
Uma Markan, Samhitha Pasupuleti, Celina M. Pollard, Arianna Perez,
Beatrix Aukszi and Anastasios Lymperopoulos

Abstract: Since the launch of the first orally available angiotensin II (AngII) type 1 receptor
(AT1R) blocker (ARB) losartan (Cozaar) in the late 1990s, the class of ARBs (or ‘sartans’,
short for Angiotensin-RecepTor-ANtagonistS) quickly expanded to include candesartan,
eprosartan, irbesartan, valsartan, telmisartan, and olmesartan. All ARBs have high affinity for
the AT1 receptor, expressed in various tissues, including smooth muscle cells, heart, kidney,
and brain. Since activation of AT1R, the target of these drugs, leads, among other effects, to
vascular smooth muscle cell growth, proliferation and contraction, activation of fibroblasts,
cardiac hypertrophy, aldosterone secretion from the adrenal cortex, thirst-fluid intake
(hypervolemia), etc., the ARBs are nowadays one of the most useful cardiovascular drug
classes used in clinical practice. However, significant differences in their pharmacological
and clinical properties exist that may favor use of particular agents over others within the
class, and, in fact, two of these drugs, candesartan and valsartan, continuously appear to
distinguish themselves from the rest of the ‘pack’ in recent clinical trials. The reason(s) for the
potential superiority of these two agents within the ARB class are currently unclear but under
intense investigation. The present short review gives an overview of the clinical properties
of the ARBs currently approved by the United States Food and Drug Administration, with a
particular focus on candesartan and valsartan and the areas where these two drugs seem
to have a therapeutic edge. In the second part of our review, we outline recent data from our
laboratory (mainly) on the molecular effects of the ARB drugs on aldosterone production and
on circulating aldosterone levels, which may underlie (at least in part) the apparent clinical
superiority of candesartan (and valsartan) over most other ARBs currently in clinical use.
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Introduction
The first angiotensin II (AngII) type 1 receptor
(AT1R) blocker (ARB) or sartan (short for
Angiotensin-RecepTor-ANtagonist) approved by
the United States Food and Drug Administration
(FDA) for hypertension was losartan in the 1990s,
rapidly followed by candesartan, eprosartan, irbesartan, valsartan, telmisartan, and olmesartan. The
ARBs bind the AT1R with high affinity.1 ARBs
were developed to complement the efficacy of
angiotensin converting enzyme inhibitors (ACEIs)
and to also do away with the major adverse effects
of the latter drug class, that is, dry cough, thought
to result from elevation of proneuro-inflammatory
http://tac.sagepub.com

bradykinin levels in the lungs (ACE activates bradykinin from precursor kinins and the vast lung
endothelium is particularly rich in this enzyme),
and angioedema (also kinin-dependent).2 ACEIs
do not completely abrogate AngII production in
the body, as synthesis of this peptide hormone can
occur via alternative enzymatic pathways, such as
chymase and other tissue-based proteases.3 These
alternative pathways can become upregulated
upon long-term ACEI use, resulting in reduced
antihypertensive efficacy. The hemodynamic
effects of ARBs are similar to those of ACEIs.
Because AngII is a very potent vasoconstrictor
peptide (second most potent endogenous
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Figure 1. Chemical structures of the individual angiotensin II (AngII) type 1 receptor (AT1R) blockers (ARBs)
discussed extensively in the present review.
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vasoconstrictor hormone behind endothelin), AT1R
blockade leads to vasodilation and reduction in
total peripheral resistance (i.e. cardiac afterload)
and blood pressure lowering.4 Cardiac output
remains unchanged. Despite BP lowering, heart
rate remains unchanged, and there is no postural
hypotension, likely because ARBs reset baroreceptor function.4

(Figure 1).12 In addition, candesartan and valsartan are known to stabilize the AT1R in its inactive
conformation, that is, they are, in essence, inverse
agonists.10–13 All ARBs in clinical use are
>10,000-fold selective for the AT1R versus AT2R,
with candesartan being among the most AT1Rselective agents.13–16

Like ACEIs, ARBs are able to protect target
organs in hypertensive patients. Indeed, longterm administration of ARBs reduces left ventricular hypertrophy, improves endothelial function,
induces destiffening of large arteries and reverse
remodeling of large and small arteries.5–7
Relaxation of large arteries leads to lowering of
central systolic and pulse pressures.8 Renal protection is observed in early diabetic nephropathy,
and proteinuria is reduced independently of the
hypotensive effect.9,10 ARBs are contrandicated in
pregnancy, in the presence of hyperkalemia, and
in bilateral renal artery stenosis.11 ARBs differ in
their AT1R binding kinetics. Candesartan is
known to confer insurmountable (noncomptetitive) antagonism at the receptor thanks to the
carboxyl group attached to its benzimidazole

side-chain (Figure 1).12 However, telmisartan,
which lacks this carboxyl moiety, and valsartan,
which has it but lacks the benzimidazole ring, also
exhibit noncompetitive antagonism of the AT1R

Clinical comparison of ARB agents
In a meta-analysis of 14 studies, comprising 8 on
hypertensive patients and 6 on heart failure (HF)
patients, candesartan was found to induce a
(albeit slightly) greater extent of blood pressure
reduction compared with losartan.17 Nevertheless,
this difference was deemed unlikely to be cost
effective. In HF patients, both ARBs were found
more or less equieffective at symptomatic
improvement.18 In one study, however, candesartan was found superior to losartan in terms of
mortality and hospitalization rate reductions,
although the fact that the losartan might have
been underdosed in the patients of this study
casts doubt on its conclusions.19 Unfortunately,
clinical head-to-head comparisons between other
ARB agents, or between candesartan or losartan
versus any other ARB agent, are still lacking.
An interesting new angle on the therapeutic efficacy of ARBs for HF was provided recently with
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the approval and market entry of Novartis’s
Entresto® (sacubitril/valsartan), the first firstin-class drug to be approved by the FDA for HF
treatment in more than two decades.20–23 In this
drug, the potent ARB valsartan is combined
with sacubitril, which is a neprilysin (NEP)
inhibitor. NEP is a neutral endopeptidase that
degrades natriuretic peptides and other vasodilating peptides, for example, substance P and
bradykinin, as well as vasoconstricting peptides,
for example, endothelin and AngII.24 In fact,
exactly because NEP inhibition can increase
AngII levels, sacubitril and all NEP inhibitors
have to be combined with an ARB for HF treatment.24 The 1:1 stoichiometric combination of
sacubitril and valsartan was shown to confer
additional clinical benefit in HF with reduced
ejection fraction (HFrEF) patients on top of
their standard treatment. Importantly, NEP
inhibition with sacubitril seems to provide clinical benefits that valsartan (Diovan) alone cannot, including reduction in the left atrial size,
reverse left atrial remodeling, and New York
Heart Association (NYHA) class improvement.21,23 In the PARADIGM trial, which pivoted Entresto® into regulatory approval in the
US and in Europe, sacubitril/valsartan conferred benefits for HFrEF patients, significantly
reducing morbidity and mortality compared
with enalapril.21 The molecular mechanisms
underlying the additional clinical benefits of
NEP inhibition when added to the ARB valsartan are presently unknown. Interestingly, however, modulation of aldosterone levels (see
below) might be a major part of this mechanism,
since natriuretic peptides inhibit aldosterone
secretion from the adrenal cortex, which means
that NEP promotes it while degrading AngII,
the major physiological stimulus for adrenal
aldosterone secretion (again, see below), at the
same time.25–28 It is thus plausible that an ARB
(e.g. valsartan) alone is insufficient to fully suppress aldosterone in HFrEF, due to elevated
overall (and obesity-specific) NEP activity, and
the addition of a NEP inhibitor (such as sacubitril in Entresto®) helps produce the additional
aldosterone suppression necessary to confer
substantial clinical benefits in human HFrEF.
In other words, the degree of adrenal-derived
aldosterone suppression may hold the mechanistic key to Entresto®’s clearly demonstrated
clinical benefits in HF. This, of course, remains
to be validated in clinical trials of HF patients

http://tac.sagepub.com

treated with Entresto® and assessing/comparing
their circulating aldosterone levels versus
patients treated with valsartan (or some other
ARB) without a NEP inhibitor.
Effects of ARBs on aldosterone production
AngII, alongside hyperkalemia, is the most
powerful physiological stimulus for adrenocortical aldosterone synthesis and secretion. This
effect is mediated by the adrenocortical AT1R,
which is a G protein-coupled receptor (GPCR)
that can signal to aldosterone production via two
independent pathways: a well-established G
protein-dependent pathway, via generation of the
second messengers diacylglycerol and inositol
trisphosphate, which ultimately upregulate StAR
(steroidogenic acute regulatory) protein, and
β-arrestin-1 (also known as Arrestin-2), which
also can upregulate StAR in the adrenal cortex via
ERK activation (Figure 2).29,30 Full blockade
of both pathways is required to suppress
adrenal aldosterone production completely.31,32
Interestingly, several ARBs have been reported to
be ineffective at lowering aldosterone in HF,
despite completely blocking the AT1R-G protein
interaction.33–38 This has prompted recent screenings of ARB efficacies at inhibiting the β-arrestin1-dependent aldosterone production. Losartan
was found largely ineffective at blocking βarrestin-1-dependent aldosterone production and
at combatting hyperaldosteronism in animal
models of HF due to very weak adrenal βarrestin-1 inhibition.30,39 In contrast, losartan’s
active metabolite (EXP1374) was an effective
suppressor of β-arrestin-1-dependent aldosterone.39 Regarding the rest of the currently FDAapproved ARBs, candesartan and valsartan were
found the most potent blockers of adrenal βarrestin-1-dependent aldosterone both in vitro
and in vivo (Figure 2).39,40 Conversely, irbesartan,
similarly to losartan, was a very weak β-arrestin-1
inhibitor, and, thus, ineffective at suppressing
aldosterone, despite its excellent G protein-inhibitory activity (Figure 2).39,40 Importantly, the
effects of these ARBs on cardiac function of HF
animals in vivo followed closely their effects on
circulating aldosterone levels, that is, candesartan
and valsartan induced significant improvements
in cardiac function and adverse remodeling,
whereas irbesartan and losartan were unable to
halt progression of myocardial infarction to fullblown HF in rats.40
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Figure 2. The two components of adrenocortical aldosterone production and the degree of their inhibition by
ARBs.

AT1R, Angiotensin II type 1 receptor; βarr1, β-arrestin-1; G prt, G protein; pERK, phospho-extracellular signal-regulated
kinase; StAR, Steroidogenic Acute Regulatory protein. The solid black inhibition sign denotes potent inhibition. The dashed
black inhibition sign denotes weak inhibition.

Although virtually next to nothing is known about
the structural requirements for β-arrestin agonism
or inverse agonism, it is interesting to point out that
both of the weak β-arrestin-1-dependent aldosterone inhibitors irbesartan and losartan lack the
side-carboxyl group present in the potent

β-arrestin-1-dependent aldosterone inhibitors candesartan and valsartan (Figure 1). Moreover,
EXP1374, losartan’s active metabolite that potently
inhibits β-arrestin-1-dependent aldosterone,39 also
has this carboxyl moiety. It is thus tempting to
speculate that carrying a second negative charge (in
addition to the indispensable tetrazole ring that
mimics the Phe8 C-terminus of AngII) is essential
not only for binding the orthosteric site of AT1R,
thereby sterically blocking receptor interaction with
AngII,41 but also potentially for β-arrestin inverse
agonism. The stereochemical space (‘bulkiness’)
occupied by the side moieties has to be taken into
account as well; for instance, a recent study demonstrated the effect of the bulkiness of the Ile5 sidechain in AngII on β-arrestin agonism at the AT1R.42
In conclusion, based on the above, the ARBs that
suppress aldosterone (including adrenal β-arrestin1-dependent aldosterone) most effectively (e.g.
candesartan, valsartan) might work better for HF
therapy. In contrast, irbesartan and losartan, both

4

weak adrenal β-arrestin-1-dependent aldosterone
inhibitors, might be therapeutically inferior for
clinical HFrEF in terms of morbidity/mortality
reduction.43–45 Of course, data on serum aldosterone levels of ARB-treated HF patients are required
to confirm or refute this mechanistically derived
pharmacological rationale. Moreover, the degree
of adrenal β-arrestin-1-dependent aldosterone
inhibition conferred by each individual ARB drug
might have a bearing on the ‘aldosterone breakthrough’ or ‘aldosterone escape’ phenomenon,
which basically describes the long-term failure to
suppress circulating aldosterone.36–38 In other
words, the more potent adrenal β-arrestin-1dependent aldosterone suppression an ARB
induces, the less its propensity for ‘aldosterone
breakthrough’ manifestation. Indeed, there is
already some experimental evidence pointing to
adrenal β-arrestin-1 as a possible culprit for the
‘aldosterone breakthrough’ or ‘aldosterone escape’
phenomenon observed with ARBs: a decade-old
study on candesartan-dependent suppression of
AngII-induced aldosterone secretion in human
adrenocortical cells in vitro suggested that bone
morphogenetic protein (BMP)-6 mediates the
resistance of these cells to candesartan’s hypoaldosteronic actions.46 Since β-arrestins are known to
enhance BMP signaling in various cell types,47 it is
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quite plausible that adrenal β-arrestin-1 activation
by the AT1R promotes AngII’s pro-aldosteronic
effects and the adrenocortical cell’s refractoriness
to AT1R blockade (with an ARB) over time, that
is, the ARB-associated ‘aldosterone breakthrough.’
The potential role of adrenal βarrestin1 in the
development of the ARB-associated ‘aldosterone
breakthrough’ phenomenon definitely warrants
further investigation in the future.
Conclusion/future perspectives
It is now clear that not all ARBs are clinically or
pharmacologically equivalent. Thus, neither are
they therapeutically equal, especially when the
treatment of a very complex syndrome such as
HF is considered. Unfortunately, studies comparing them head-to-head are very scarce and
inconclusive. Based on the very limited data available as of now, certain agents (candesartan, valsartan) seem to stand out from their class both
clinically and pharmacologically. In the present
review, we have presented some molecular evidence for why these two ARBs in particular might
be superior over others in the same class: the reason may lie in the degree of adrenal aldosterone
suppression, and, more specifically, in the extent
of inhibition of the adrenal β-arrestin-1 component of aldosterone production. The level of
aldosterone suppression afforded may even hold
the key to the apparent therapeutic success of the
sacubitril/valsartan combination recently introduced into clinical practice. This hypothesis is
definitely worth investigating in the future. Of
course, there is currently no clinical evidence that
ARBs are superior to ACE inhibitors for patients
with HFrEF, and more comprehensive prospective comparative head-to-head trials of the ARBs
to evaluate their relative efficacy at preventing
aldosterone escape or breakthrough are definitely
warranted. However, given the complex hormonal interplay underlying HF pathophysiology, in
which AngII and aldosterone play prominent
roles, the fields of ARB pharmacology, and, more
broadly, of the renin-angiotensin-aldosterone system, are bound to keep HF specialists and cardiovascular scientists alike on edge for new discoveries
and therapeutic advances for many years to come.
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